• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
PARI Pharma GmbH - Product Pipeline Review - Q4 2010 Product Image

PARI Pharma GmbH - Product Pipeline Review - Q4 2010

  • ID: 1463997
  • December 2010
  • 38 pages
  • Global Markets Direct

PARI Pharma GmbH – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “PARI Pharma GmbH - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- PARI Pharma GmbH - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of PARI Pharma GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
PARI Pharma GmbH Snapshot
PARI Pharma GmbH Overview
Key Information
Key Facts
PARI Pharma GmbH – Research and Development Overview
Key Therapeutic Areas
PARI Pharma GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PARI Pharma GmbH – Pipeline Products Glance
PARI Pharma GmbH – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
PARI Pharma GmbH Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
PARI Pharma GmbH–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
PARI Pharma GmbH – Drug Profiles
Anti-inflammatory drug
Product Description
Mechanism of Action
R&D Progress
Pari Tobramycin 100
Product Description
Mechanism of Action
R&D Progress
L-CsA
Product Description
Mechanism of Action
R&D Progress
Anti-cholinergic drug
Product Description
Mechanism of Action
R&D Progress
Disodium cromoglycate (DSCG)
Product Description
Mechanism of Action
R&D Progress
Levofloxacin vibrENT
Product Description
Mechanism of Action
R&D Progress
PARI Pharma GmbH – Pipeline Analysis
PARI Pharma GmbH – Pipeline Products by Therapeutic Class
PARI Pharma GmbH Pipeline Products By Target
PARI Pharma GmbH – Pipeline Products by Route of Administration
PARI Pharma GmbH – Pipeline Products by Molecule Type
PARI Pharma GmbH – Recent Pipeline Updates
PARI Pharma GmbH – Locations And Subsidiaries
Head Office
Recent Developments
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Feb 11, 2010: PARI Pharma Initiates Enrollment In Phase IIb Study Of Liposomal Cyclosporine Against Bronchiolitis Obliterans
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
May 20, 2009: PARI Pharma’s Nebulized DSCG Shows Results Similar To Inhaled Steroids In Asthma Studies Presented At ATS
May 07, 2009: PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin – eFlow Technology Program Forward
Nov 10, 2008: PARI Pharma Completes Successful Clinical Trials For Tobramycin 100 & Investigational eFlow For Cystic Fibrosis
Financial Deals Landscape
PARI Pharma GmbH, Deals Summary, 2004 to 2010
PARI Pharma GmbH Detailed Deal Summary
Activaero Enters Into Agreement With PARI Pharma
PARI Aerosol Enters Into Agreement With Kamada
Licensing Agreements
Kamada Enters Into Licensing Agreement With PARI Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS